Humoral Immune Responses after an Omicron-Adapted Booster BNT162b2 Vaccination in Patients with Lymphoid Malignancies

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt


  • Fulltext

    Forlagets udgivne version, 832 KB, PDF-dokument

To accommodate waning COVID-19 vaccine immunity to emerging SARS-CoV-2 variants, variant-adapted mRNA vaccines have been introduced. Here, we examine serological responses to the BA.1 and BA.4-5 Omicron variant-adapted BNT162b2 COVID-19 vaccines in people with lymphoid malignancies. We included 233 patients with lymphoid malignancies (chronic lymphocytic B-cell leukemia: 73 (31.3%), lymphoma: 89 (38.2%), multiple myeloma/amyloidosis: 71 (30.5%)), who received an Omicron-adapted mRNA-based COVID-19 vaccine. IgG and neutralizing antibodies specific for the receptor-binding domain (RBD) of SARS-CoV-2 were measured using ELISA-based methods. Differences in antibody concentrations and neutralizing capacity and associations with risk factors were assessed using mixed-effects models. Over the period of vaccination with an Omicron-adapted COVID-19 vaccine, the predicted mean concentration of anti-RBD IgG increased by 0.09 log10 AU/mL/month (95% CI: 0.07; 0.11) in patients with lymphoid malignancies across diagnoses. The predicted mean neutralizing capacity increased by 0.9 percent points/month (95% CI: 0.2; 1.6). We found no associations between the increase in antibody concentration or neutralizing capacity and the variant included in the adapted vaccine. In conclusion, a discrete increase in antibody concentrations and neutralizing capacity was found over the course of Omicron-adapted vaccination in patients with lymphoid malignancies regardless of the adapted vaccine variant, indicating a beneficial effect of Omicron-adapted booster vaccination in this population.

Udgave nummer1
Antal sider15
StatusUdgivet - 2024

Bibliografisk note

Funding Information:
This work was funded by the Novo Nordisk Foundation (NFF205A0063505 and NNF20SA0064201), the Carlsberg Foundation (CF20-476 0045), the Svend Andersen Research Foundation (SARF2021), Bio- and Genome Bank Denmark, and the Research Foundation at Rigshospitalet. The funding sources of the study had no role in the study design, data analysis, data interpretation, writing of the manuscript, or the decision to submit the paper for publication.

Funding Information:
L.D.H., C.B.H., K.F., S.R.H., L.P.-A., R.B.H., D.L.M., A.O.G., S.R.O., R.F.-S., E.S., L.H., H.B., P.G. and K.I. declare no conflicts of interests concerning this manuscript. M.P.-H. has received travel grants from the Augustinus Foundation, the William Demant Foundation, the Copenhagen University Research Foundation, and Familien Hede Nielsen’s Foundation. M.P.-H. has further received an independent research grant form Dagmar Marshall’s Foundation. C.S. has received honoraria from Gilead, ViiV Healthcare, and MSD. S.D.N. has received unrestricted grants from The Novo Nordisk Foundation, and Sofus Carl Emil Friis and Wife Olga Doris Friis Scholarship. S.D.N. has further received honoraria from Gilead and MSD and has served on advisory boards for Gilead, MSD, and GSK. K.G. has received grants from Janssen Pharma, the Danish Cancer society, the Novo Nordisk Foundation, the Independent Research Fund Denmark, Stand Up to Cancer, and the Research Committee at Rigshospitalet, all unrelated to this work. K.G. has further received honoraria from GSK and served on advisory boards for GSK, Nanexa, Evaxion, and Faron.

Publisher Copyright:
© 2023 by the authors.

ID: 381885881